Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7872361 | 0.78 | HPGD (0.43) | HPGDNPSR1CHRM2RAB9ANPC1 | |
| SCHEMBL4714385 | 0.78 | ALDH1A1 (0.46) | NPSR1ALDH1A1TSHRGAASMN1; SMN2 | |
| SCHEMBL30840811 | 0.78 | ALDH1A1 (0.46) | NPSR1ALDH1A1TSHRGAASMN1; SMN2 | |
| SCHEMBL27287808 | 0.77 | DRD3 (0.47) | CHRM2ALDH1A1 | |
| SCHEMBL6716400 | 0.77 | HPGD (0.55) | HPGDNPSR1RAB9ANPC1ALDH1A1 | |
| SCHEMBL9827776 | 0.76 | GLS (0.50) | CHRM2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25042572 | 0.75 | HPGD (0.50) | HPGDNPSR1RAB9ANPC1ALDH1A1 | |
| SCHEMBL10954191 | 0.75 | HPGD (0.50) | HPGDNPSR1RAB9ANPC1ALDH1A1 | |
| SCHEMBL30274324 | 0.75 | HPGD (0.50) | HPGDNPSR1RAB9ANPC1ALDH1A1 | |
| SCHEMBL9836693 | 0.75 | MAPK1 (0.52) | RAB9ANPC1ALDH1A1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541373-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-04-30 | — | — | US | disclosed |
| EP-3541373-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093694-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN1A, SCN7A | HPGD 2602/4885NPSR1 184/4885CHRM2 640/4885 |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN1A, SCN7A | HPGD 2602/4885NPSR1 184/4885CHRM2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.